Molecular Function

Gate Bioscience Captures $65M Series B to Advance Molecular Gate Protein Degradation Platform

4 weeks ago talkbio0Tagged Bio + Health, eli lilly, Forbion, Gate Bioscience, innovation, Molecular Gates, Precision Medicine, Protein Degradation, Metabolic, protein elimination therapeutics, Series B funding

Gate Bioscience; protein degradation; protein elimination therapeutics; Series B funding; Molecular Gates; Eli Lilly; Forbion; a16z Bio + Health; precision medicine; biotech innovation

ChemDiv’s Discovery Platform Enables Differentiated, Reversible Pan-EGFR Kinase Inhibitors for GFR-Mutant Lung Cancer

1 month ago talkbio0Tagged Candidiasis, Chronic Mucocutaneous, ChemDiv, Discovery Platform, Drug Design, Epidermal Growth Factor Receptor, Kinase Inhibitors [MoA], Kinome, lead-optimization, Non-Small Cell Lung Carcinoma, Pan-EGFR Inhibitors, Readiness, selectivity, Wild-Type EGFR Sparing

ChemDiv; Discovery Platform; EGFR; Reversible Pan-EGFR Inhibitors; NSCLC; Kinase Inhibitors; Wild-Type EGFR Sparing; Kinome Selectivity; AI-Guided Drug Design; CMC Readiness; Lead Optimization

BMS Breaks Clinical Losing Streak with Positive Phase 3 Myeloma Readout for Iberdomide

3 months ago talkbio0Tagged CELMoD, Clinical Trials, EXCALIBER-RRMM, iberdomide, Minimal Residual Disease Negativity, Multiple Myeloma, Myers, Phase 3, Progression-Free Survival, Protein Degradation, Metabolic, Relapsing course, squibb, Unresponsive to Treatment

Bristol Myers Squibb; iberdomide; multiple myeloma; clinical trial; EXCALIBER-RRMM; minimal residual disease negativity; CELMoD; protein degradation; progression-free survival; phase 3; relapsed or refractory

Novartis Bets on Covalent Chemistry in $1B Matchpoint Therapeutics Deal

5 months ago talkbio0Tagged Advanced phase, biotechnology partnerships, covalent chemistry, Covalent Interaction, Drug Development, Inflammatory disorder, License, Matchpoint Therapeutics, Novartis, oral inhibitors

Novartis; Matchpoint Therapeutics; covalent chemistry; exclusive option and license agreement; inflammatory diseases; oral inhibitors; Advanced Covalent Exploration platform; drug development; biotechnology partnerships

Advancements in Predicting Tumor Response and Expanding Therapy Eligibility Using Epigenomic Biomarkers

5 months ago talkbio0Tagged Biological Markers, Diagnostics, DNA Methylation, Epigenomics, personalized cancer therapy, Prediction, tumor response

epigenomic biomarkers; tumor response prediction; personalized cancer therapy; DNA methylation; AI-driven diagnostics

MIT’s Boltz-1 AI Model Rivals AlphaFold 3 in Biomolecular Structure Prediction

6 months ago talkbio0Tagged AlphaFold, Artificial Intelligence, biomolecular structure prediction, Boltz-1, Drug Discovery, MIT, open-source AI, protein folding

MIT; Boltz-1; AlphaFold 3; AI model; biomolecular structure prediction; drug discovery; protein folding; open-source AI

Kymera Soars on Early Protein Degrader Data

6 months ago talkbio0Tagged Autoimmune Diseases, Clinical Trials, KT-621, Kymera, Phase 1 (qualifier value), Protein Degradation, Metabolic, STAT6 degrader

Kymera Therapeutics; KT-621; STAT6 degrader; protein degradation; Phase 1 clinical trial; autoimmune disease

Boundless Bio Lays Off 33% of Staff Following Stumble of Lead Program

7 months ago talkbio0Tagged BBI-355, BBI-825, Bio, Boundless, CHEK1 protein, human, Clinical Trials, Combined Modality Therapy, Inhibitor, layoffs, pipeline restructuring, ribonucleoside-diphosphate reductase activity, Solid Neoplasm

Boundless Bio; layoffs; biotech; clinical trial; BBI-355; BBI-825; RNR inhibitor; CHK1 inhibitor; combination therapy; solid tumors; pipeline restructuring

PRISM BioLab and Elix Collaborate to Revolutionize AI-Driven Drug Discovery with Peptide Mimetics

8 months ago talkbio0Tagged Artificial Intelligence, Drug Discovery, Efficiency, Elix, mimetics, PepMetics, Peptides, pharmaceutical innovation, PRISM BioLab, Protein-Protein Interaction, small molecule inhibitors

PRISM BioLab , Elix , AI drug discovery , Peptide mimetics , Protein-protein interactions , PepMetics® , Small molecule inhibitors , Drug discovery efficiency , Pharmaceutical innovation

TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases

9 months ago talkbio0Tagged cellular targeting, Clinical Nurse Specialists, degraders, Neurodegenerative Disorders, Protein Degradation, Metabolic, TRIM21, TRIMTAC

targeted protein degradation, neurodegenerative diseases, TRIM21, TRIMTAC degraders, CNS therapeutics, seed funding, biotech startup